Ongoing Trials
- A multicenter trial assessing the impact of Lp(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis (Lp(a)FRONTIERS CAVS) (NCT05646381)
- Assessing the impact of Lp(a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients with CVD (Lp(a)HORIZON) (NCT04023552)
Completed Trials
- Multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the rate of weekly lipoprotein apheresis sessions in patients with hyperlipoproteinemia(a) and established cardiovascular disease in Germany (Lp(a)FRONTIERS APHERESIS, NCT05305664)
- Phase 2 study of pelacarsen (ISIS 681257; AKCEA-APO(a)-LRx) in participants with hyperlipoproteinemia(a) and cardiovascular disease
